Group 1 - Janus Henderson Forty Fund reported a return of 0.27% in Q4 2025, underperforming the Russell 1000® Growth Index, which returned 1.12% [1] - The fund's performance was positively influenced by stock selection in the healthcare and consumer staples sectors, while the information technology and consumer discretionary sectors detracted from performance [1] - The fund remains optimistic about the market environment in 2026, supported by steady economic growth [1] Group 2 - Eli Lilly and Company (NYSE: LLY) was highlighted as a leading contributor to the fund's performance, with a market capitalization of $802.832 billion [2] - Eli Lilly's stock closed at $897.00 per share on March 26, 2026, with a one-month return of -14.73% and a 52-week gain of 9.06% [2] - The company reported strong third-quarter results driven by sales growth of its GLP-1 weight loss products, Mounjaro and Zepbound, and has promising pipeline drugs in late-stage clinical trials [3] - Eli Lilly reached an agreement with the U.S. government regarding pricing and access to GLP-1 drugs for Medicare and Medicaid users, potentially expanding the market for its weight loss drugs [3]

Core Insights - Eli Lilly and Novo Nordisk, leaders in the obesity drug market, have underperformed compared to broader equities, with Novo Nordisk lagging more significantly. Analysts expect substantial growth in this therapeutic area over the next decade, with both companies likely to maintain their competitive edge due to their pipelines [1] Comparison of Weight Loss Portfolios - Eli Lilly's Zepbound outperformed Novo Nordisk's Wegovy in a clinical trial, achieving a mean weight loss of 20.2% compared to Wegovy's 13.7% over 72 weeks. Zepbound has gained significant market traction despite Wegovy's earlier approval [1] - Novo Nordisk has launched an oral version of Wegovy and received approval for a high-dose formulation. Additionally, it is developing CagriSema, a next-generation anti-obesity therapy that has shown better results than Wegovy in clinical studies [2] Competitive Landscape - Novo Nordisk is developing UBT251, which mimics the action of three gut hormones and has shown promising results in a phase 2 clinical trial in China. However, Eli Lilly is set to launch its own oral GLP-1, orforglipron, which targets both weight loss and diabetes, outperforming Novo Nordisk's Rybelsus in head-to-head studies [3][4] - Eli Lilly's retatrutide has demonstrated exceptional results in a phase 3 study, achieving a mean weight loss of 28.7% at its highest dose after 68 weeks, outperforming all other drugs in the market. This suggests that Eli Lilly's weight loss portfolio is stronger than that of Novo Nordisk [5]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests focusing on domestic biotech companies with differentiated competitive advantages [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 2.77% from March 16 to March 20, underperforming the CSI 300 index, which fell by 2.19%. Medical consumables, raw materials, and vaccines were the leading sub-sectors, while medical devices and outsourced medical research saw the largest declines [2][7]. - A significant milestone was achieved on March 21 when Dizhe Pharmaceutical announced positive top-line results from its Phase III clinical trial for its core product, Shuwotai (suwonitinib), for the treatment of EGFR exon20ins mutation advanced non-small cell lung cancer. This marks the first oral monotherapy to achieve positive results in this indication globally, indicating a breakthrough for domestic small molecule TKI drugs [2][10]. Market Weekly Review - The pharmaceutical and biotechnology sector declined by 2.77%, underperforming the CSI 300 index, which fell by 2.19%. The leading sub-sectors included medical consumables (4.1%), raw materials (1.32%), and vaccines (1.29%), while medical devices (-2.04%), outsourced medical research (-1.63%), and chemical preparations (-0.82%) lagged behind. Notable stock performances included *ST Jingfeng (27.7%), Sanofi (23.1%), and Jidan Bio (15.6%) for gains, while *ST Changyao (-52.2%), Xiangyu Medical (-21.4%), and Sanbo Brain Science (-20.7%) faced significant losses [2][7][10]. Industry News and Key Company Announcements - On March 21, Dizhe Pharmaceutical announced that its new targeted lung cancer drug, Shuwotai, achieved positive results in a Phase III clinical trial for treating advanced non-small cell lung cancer with EGFR exon20ins mutation, marking a significant advancement in the field [10]. - On March 20, Novartis announced an agreement to acquire Pikavation Therapeutics for a total potential cash consideration of up to $3 billion, including a $2 billion upfront payment and $1 billion in milestone payments [13]. - Eli Lilly reported positive results from its Phase III trial for a new treatment for type 2 diabetes, showing significant reductions in HbA1c levels and weight loss among patients [13]. - Aiming for growth, various companies reported their annual earnings, with notable performances from Dong'e Ejiao, which saw a revenue increase of 8.83%, and Tianjin Tasly, which reported a revenue decrease of 3.08% [13][14].

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests focusing on domestic biotech companies with differentiated competitive advantages. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 2.77% from March 16 to March 20, underperforming the CSI 300 index, which fell by 2.19%. Notably, medical consumables, raw materials, and vaccines showed positive growth, while medical devices and chemical preparations faced declines. Individual stock performances varied significantly, with *ST Jingfeng rising by 27.7% and *ST Changyao dropping by 52.2% [2][7][10]. - A significant milestone was achieved by Dize Pharmaceutical on March 21, with its core product, Shuwotai (舒沃替尼), demonstrating positive results in a Phase III clinical trial for treating advanced non-small cell lung cancer with EGFR exon20ins mutations. This marks a breakthrough in the availability of oral monotherapy options in this field and highlights the potential of Chinese biotech companies to innovate and compete globally [2][10]. Market Weekly Review - The pharmaceutical and biotechnology sector declined by 2.77%, underperforming the CSI 300 index, which fell by 2.19%. Medical consumables (4.1%), raw materials (1.32%), and vaccines (1.29%) led the gains, while medical devices (-2.04%), medical research outsourcing (-1.63%), and chemical preparations (-0.82%) faced losses. Notable stock performances included *ST Jingfeng (27.7%), Sanofi (23.1%), and Jidan Biology (15.6%) for gains, while *ST Changyao (-52.2%), Xiangyu Medical (-21.4%), and Sanbo Brain Science (-20.7%) faced significant declines [2][7][10]. Industry News and Key Company Announcements - On March 21, Dize Pharmaceutical announced that its new targeted lung cancer drug, Shuwotai (舒沃替尼), achieved positive results in a Phase III clinical trial for treating advanced non-small cell lung cancer with EGFR exon20ins mutations, becoming the first oral targeted drug to achieve such results in an international multi-center study [10]. - On March 20, Novartis announced an agreement to acquire Pikavation Therapeutics for a total potential cash consideration of up to $3 billion, including an upfront payment of $2 billion and milestone payments of $1 billion [13]. - Eli Lilly reported positive results from its Phase III trial for a new treatment for type 2 diabetes, showing significant reductions in HbA1c levels and weight loss among patients [13]. - Other companies, such as Aimeike and Dong'e Ejiao, reported their annual earnings, with Aimeike experiencing a revenue decline and Dong'e Ejiao showing revenue growth [13][15].

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The innovative drug sector is experiencing significant funding support, with a total of approximately 700 billion RMB raised in the A-share and Hong Kong markets from January 1, 2024, to March 21, 2026, to support R&D investments [15] - The BD (Business Development) income has become a crucial funding source for innovative drug research, with total contracts reaching 57.1 billion USD as of March 21, 2026, indicating a strong trend in the Chinese innovative drug market [18] - The report highlights a positive outlook for the innovative drug sector, particularly in small nucleic acid therapies, and suggests a ranking of preferred sub-sectors: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies [8][11] Summary by Sections Industry Performance - The A-share pharmaceutical index has seen a decline of 2.77% this week and 2.90% year-to-date, underperforming the CSI 300 by 0.59% and 1.54% respectively [8] - The Hong Kong biotechnology index has increased by 0.48% this week and decreased by 0.97% year-to-date, outperforming the Hang Seng Technology Index by 2.60% and 10.63% respectively [8] Funding and Investment - From January 1, 2024, to March 21, 2026, the A-share pharmaceutical sector raised 11.8 billion RMB through equity financing and 2.5 billion RMB through convertible bonds [15] - The report emphasizes that the current funding situation in the pharmaceutical sector is robust, with most companies maintaining over one year of R&D funding coverage [18] R&D Progress and Company Developments - Several companies have made significant advancements in their R&D pipelines, including KX-826 for hair loss treatment and ABSK061 for achondroplasia, which received orphan drug designation from the FDA [8] - The report suggests specific companies to watch based on various therapeutic areas, including innovative drugs, ADCs, and small nucleic acids [11] Market Insights - The report notes that the overall market for pharmaceuticals is currently undervalued, with the pharmaceutical index trading at a P/E ratio of 35.19, which is 3.22 times lower than its historical average [8]

Investment Rating - The report maintains a rating of "Buy" for the pharmaceutical and biotechnology industry [1] Core Insights - The innovative drug sector is experiencing significant funding support, with a total of approximately 700 billion RMB raised in the A-share and Hong Kong markets from January 1, 2024, to March 21, 2026, to support R&D investments [15] - The BD (Business Development) income has become a crucial funding source for innovative drug research, with total contracts reaching 57.1 billion USD as of March 21, 2026, indicating a strong trend in the Chinese innovative drug market [18] - The report highlights a positive outlook for the innovative drug sector, particularly in small nucleic acid therapies, and suggests a ranking of preferred sub-sectors: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies [8] Summary by Sections Industry Performance - The A-share pharmaceutical index has seen a decline of 2.77% this week and 2.90% year-to-date, underperforming the CSI 300 by 0.59% and 1.54% respectively [8] - The Hong Kong biotechnology index has increased by 0.48% this week and decreased by 0.97% year-to-date, outperforming the Hang Seng Technology Index by 2.60% and 10.63% respectively [8] Funding and Investment - From January 1, 2024, to March 21, 2026, the A-share pharmaceutical sector raised 11.8 billion RMB through equity financing and 2.5 billion RMB through convertible bonds [15] - The Hong Kong pharmaceutical sector raised a total of 63.2 billion HKD during the same period [15] R&D Progress and Company Developments - Several companies have made significant advancements in their R&D, including KX-826 for hair loss treatment and ABSK061 for achondroplasia, which received orphan drug designation from the FDA [8] - The report emphasizes the importance of maintaining a robust financial foundation for ongoing clinical trials and pipeline expansion, with most companies having over one year of R&D funding coverage [18] Stock Recommendations - The report suggests focusing on specific companies based on various therapeutic areas, including innovative drugs, ADCs, small nucleic acids, and traditional Chinese medicine [11]

Eli Lilly’s experimental weight-loss drug retatrutide met the primary and key secondary endpoints in a trial, showing significant reductions in weight loss and blood sugar levels. https://t.co/OFBUzypgGt ...

Core Viewpoint - Eli Lilly has experienced a decline in share price since reaching a $1 trillion market valuation, with concerns about its valuation and potential competition in the weight management market [1] Group 1: Market Position and Competition - Eli Lilly maintains a strong lead in the anti-obesity market, with new product launches expected to solidify its position and expand its market reach [2] - The company is preparing to launch orforglipron, an oral GLP-1 candidate, which could attract new patients who prefer oral therapies over subcutaneous options [2] - Orforglipron has shown strong clinical trial performance, positioning it as a potential best-in-class medicine in diabetes and obesity treatment [3] Group 2: Product Pipeline and Revenue Sources - Eli Lilly is targeting patients with high body mass indexes with retatrutide, which has demonstrated a remarkable 28.7% mean weight loss in a phase 3 study [3][4] - The company has a diverse portfolio beyond weight management, including billion-dollar drugs like Verzenio, which generated $5.7 billion in sales last year, and Taltz, which grew sales by 9% to $3.6 billion [6][7] - Eli Lilly's aggressive expansion into various therapeutic areas, including pain management, oncology, and immunology, supports its revenue growth strategy [7] Group 3: Valuation and Growth Potential - Eli Lilly trades at a forward earnings multiple of 27x, significantly higher than the healthcare sector average of 17.1x, reflecting its faster revenue and earnings growth compared to peers [8] - The company's deep pipeline of candidates is expected to drive growth in the medium term, making the stock attractive despite its premium valuation [8]

Eli Lilly’s experimental drug retatrutide met trial endpoints, showing significant weight loss and blood sugar reductions. https://t.co/t4a97OCbBI ...

Core Insights - Eli Lilly is well-positioned to attract future investments in India due to its strong scientific base, academic resources, and skilled workforce [1][10] - The company emphasizes the importance of regulatory data protection and a streamlined regulatory review process to enhance India's competitiveness in attracting high-value research [2][11] - Lilly's performance has been robust, driven by innovative medicines addressing significant unmet medical needs, with a positive outlook for future growth [7][8] Regulatory Environment - Regulatory data protection is crucial for the pharmaceutical industry, allowing companies to recoup investments made in clinical efficacy and safety data [2][5] - The regulatory review process in India involves three steps and can take up to one and a half years, which could be improved for faster approvals [2][11] - Harmonization with international guidelines for clinical trials is necessary to strengthen India's scientific capabilities and enable earlier access to innovative therapies [2][11] Market Dynamics - The affordability of medicines in India reflects the country's GDP per capita, ensuring that prices are significantly lower than in markets like Germany or the U.S. [6][11] - The innovative pharmaceutical industry is essential for the existence of generics, highlighting the interdependence between innovative and generic drug markets [5][11] Product Pipeline - Eli Lilly is expanding its product pipeline with significant developments in areas such as type 2 diabetes, obesity, Alzheimer's disease, and oncology [7][9] - The company plans to launch Donanemab for Alzheimer's in India by 2026, subject to regulatory approvals, and has an oral GLP-1 under review outside India [9][11] - Retatrutide, a triple agonist, has shown promising results with over 28% weight loss in studies, indicating strong potential in the obesity treatment market [9][11]